Of women will develop uterine fibroid by the age of 50
Of women with fibroids are symptomatic
Of women with fibroids are on therapeutic plan
Of surgeries performed in US are hysterectomies
Myomectomy is The Golden Standard of Care for Uterine Preservation and Future Pregnancy Option.
Minimally Invasive or Laparoscopic Myomectomy Was First Described in the Late 1970’s
It is a Difficult Technique which has not Developed since the early 1990’s
The Empress system is intended to treat symptomatic uterine fibroids, in a laparoscopic procedure, by inducing fibroid tissue ischemia.
Sutures wrapped around the fibroid increases the intra-tumoral pressure which leads to fibroid Ischemia – blockage of intra- and peri-fibroid blood flow and, eventually, necrosis of the fibroid tissue.
21 uterine fibroids were treated in 16 symptomatic pre-menopausal black women. Pelvic magnetic resonance imaging (MRI) was performed before the procedure, and at 1, 3, 6, and 12 months.
Results suggest the device is safe and can be effective for its intended purpose
Empress’ Founder & Chairman
Interventional Radiologist Former Associate Clinical Professor of Radiology at Yale University School of Medicine, US
Managing Partner of Med Venture Holdings
Former president of Cooper Surgical
Head of Advisory Board
FACOG, Female Pelvic Medicine and Reconstructive Surgery, Urogynecology
Advisory Board Member
OBGYN Surgeon, Specializing in advanced Endoscopy
VP Business Development
Experienced manager and business consultant of medical device funds and startups
An accomplished CEO and CMO with a track record of driving growth through strategic marketing integration, adept at thriving in fast-paced environments and startup ventures across global markets, and a passionate advocate for FemTech.
Deep technical background and experience in development and production of medical devices
Vast experience in regulation and certification of medical devices
Over 15 years as a CFO in startups and corporations